Comparison of the efficacy and adverse effects of oral ferrous succinate tablets and intravenous iron sucrose: a retrospective study.
Humans
Male
Female
Ferric Oxide, Saccharated
/ administration & dosage
Retrospective Studies
Middle Aged
Anemia, Iron-Deficiency
/ drug therapy
Administration, Oral
Adult
Ferrous Compounds
/ administration & dosage
Tablets
Hemoglobins
/ analysis
Treatment Outcome
Administration, Intravenous
Hematinics
/ administration & dosage
Aged
Ferritins
/ blood
Adverse drug reaction
Ferrous succinate tablet
Iron deficiency anaemia
Iron sucrose injection
Journal
BMC pharmacology & toxicology
ISSN: 2050-6511
Titre abrégé: BMC Pharmacol Toxicol
Pays: England
ID NLM: 101590449
Informations de publication
Date de publication:
03 Sep 2024
03 Sep 2024
Historique:
received:
25
01
2024
accepted:
22
07
2024
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
3
9
2024
Statut:
epublish
Résumé
To analyse the clinical efficacy and adverse drug reactions (ADRs) of iron preparations. A total of 374 patients with iron deficiency anaemia admitted to our hospital between 1 January and 31 December 2020 were included in this study. They were divided into 2 groups based on their medication regimens: Group A (n = 187) took oral ferrous succinate tablets, and Group B (n = 187) received intravenous iron sucrose. The remission of major symptoms, laboratory test results, ADRs and other related data were collected after 4 weeks of treatment. Compared with the pre-treatment baseline, haemoglobin (Hb), serum iron (SI), serum ferritin (SF) and the mean corpuscular volume (MCV) increased in both groups at 4 weeks of treatment (P < 0.05). After treatment, Group A had lower levels of Hb (108.41 ± 8.39 vs. 122.31 ± 6.04 g/L, t = 6.293, P < 0.001), SI (9.72 ± 4.24 vs. 15.62 ± 5.41 µmol/L, t = 5.482, P < 0.001) and SF (27.1 ± 10.82 vs. 39.82 ± 10.44 ug/L, t = 6.793, P < 0.001) compared with Group B. In contrast, there was no significant difference in the post-treatment level of MCV (P > 0.05). The overall response rate significantly differed between the 2 groups (78.61% vs. 90.91%, χ Iron sucrose demonstrates favourable efficacy and safety in treating iron deficiency anaemia.
Identifiants
pubmed: 39227996
doi: 10.1186/s40360-024-00769-z
pii: 10.1186/s40360-024-00769-z
doi:
Substances chimiques
Ferric Oxide, Saccharated
FZ7NYF5N8L
Ferrous Compounds
0
ferrous succinate
818ZYK7N91
Tablets
0
Hemoglobins
0
Hematinics
0
Ferritins
9007-73-2
Types de publication
Journal Article
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
61Informations de copyright
© 2024. The Author(s).
Références
Wang SF. Function and mechanism of transferrin receptor 1 in the hemopoietic system. Zhejiang University; 2020.
Chinese Nutrition Society Iron-Deficiency Anemia Prevention and Control Section. Expert consensus on nutrition control of iron‐deficiency anemia. Acta Nutrimenta Sinica. 2019;41(5):417–26.
Li R. Mechanistic study of iron-mediated resistance to PVYN. Shenyang Agricultural University; 2020.
Hagag AA, Badraia IM, Abdelmageed MM, Hablas NM, Hazzaa SME, Nosair NA. Prognostic value of transferrin Receptor-1 (CD71) expression in Acute Lymphoblastic Leukemia. Endocr Metab Immune Disord Drug Targets. 2018;18(6):610–7. https://doi.org/10.2174/1871530318666180605094706 .
doi: 10.2174/1871530318666180605094706
pubmed: 29875008
Camiolo G, Barbato A, Giallongo C, Vicario N, Romano A, Parrinello NL, Parenti R, Sandoval JC, García-Moreno D, Lazzarino G, Avola R, Palumbo GA, Mulero V, Li Volti G, Tibullo D, Di Raimondo F. Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib. Redox Biol. 2020;36:101611. https://doi.org/10.1016/j.redox.2020.101611 .
doi: 10.1016/j.redox.2020.101611
pubmed: 32863212
pmcid: 7327252
Garofalo V, Condorelli RA, Cannarella R, Aversa A, Calogero AE, La Vignera S. Relationship between Iron Deficiency and thyroid function: a systematic review and meta-analysis. Nutrients. 2023;15(22):4790. https://doi.org/10.3390/nu15224790 .
doi: 10.3390/nu15224790
pubmed: 38004184
pmcid: 10675576
Liu ZH, Zhang HM. Two iron preparations for anemia treatment in pregnancy. Chin Remedies Clin. 2020;20(15):2571–2.
DeLoughery TG. Safety of oral and intravenous Iron. Acta Haematol. 2019;142(1):8–12. https://doi.org/10.1159/000496966 .
doi: 10.1159/000496966
pubmed: 30970354
Pandey AK, Gautam D, Tolani H, Neogi SB. Clinical outcome post treatment of anemia in pregnancy with intravenous versus oral iron therapy: a systematic review and meta-analysis. Sci Rep. 2024;14(1):179. https://doi.org/10.1038/s41598-023-50234-w . Published 2 Jan 2024.
Adler M, Herrera-Gómez F, Martín-García D, Gavid M, Álvarez FJ, Ochoa-Sangrador C. The impact of Iron Supplementation for treating Anemia in patients with chronic kidney disease: results from pairwise and network Meta-analyses of Randomized controlled trials. Pharmaceuticals (Basel). 2020;13(5):85. https://doi.org/10.3390/ph13050085 .
doi: 10.3390/ph13050085
pubmed: 32365757
Müller F, Dormann H, Pfistermeister B, Sonst A, Patapovas A, Vogler R, Hartmann N, Plank-Kiegele B, Kirchner M, Bürkle T, Maas R. Application of the Pareto principle to identify and address drug-therapy safety issues. Eur J Clin Pharmacol. 2014;70(6):727–36. https://doi.org/10.1007/s00228-014-1665-2 .
doi: 10.1007/s00228-014-1665-2
pubmed: 24652477
Committee of Experts on Rational Drug Use of National Health Committee of the P. R. China, Chinese Pharmacists Association. Guidelines for rational medication for coronary heart disease (2nd edition). Chin J Front Med Science(Electronic Version). 2018;10(06):1–130.
Li JT. Status quo of clinical pharmacology in western countries. Antibiotics. 1979(06):53–66.
Ramos SF, Alvarez NR, Dos Santos Alcântara T, Sanchez JM, da Costa Lima E, de Lyra Júnior DP. Methods for the detection of adverse drug reactions in hospitalized children: a systematic review. Expert Opin Drug Saf. 2021;20(10):1225–36. https://doi.org/10.1080/14740338.2021.1924668 .
doi: 10.1080/14740338.2021.1924668
pubmed: 33926346
Kong XH. Analysis of the characteristics of 82425 inpatients with drug-induced severe leukopenia and granulocytopenia. Chin J Clin Pharmacol. 2021;37(18):2503–7.
Carracedo-Reboredo P, Liñares-Blanco J, Rodríguez-Fernández N, Cedrón F, Novoa FJ, Carballal A, Maojo V, Pazos A, Fernandez-Lozano C. A review on machine learning approaches and trends in drug discovery. Comput Struct Biotechnol J. 2021;19:4538–58. https://doi.org/10.1016/j.csbj.2021.08.011 .
doi: 10.1016/j.csbj.2021.08.011
pubmed: 34471498
pmcid: 8387781
Renal Anemia Diagnosis and Treatment Group of Nephrology Society of Chinese Medical Association, Qian JL, Chen YP. Chinese expert consensus on diagnosis and treatment of renal anemia. Chin J Nephrol, 2013(05):389–92.
Zhang YL. Cost-effectiveness analysis of three iron supplements for treating pediatric patients with iron‐deficiency anemia. Natl Med Front China. 2012;7(05):73–4.
Breymann C, Honegger C, Hösli I, Surbek D. Diagnosis and treatment of iron-deficiency anaemia in pregnancy and postpartum. Arch Gynecol Obstet. 2017;296(6):1229–34. https://doi.org/10.1007/s00404-017-4526-2 .
doi: 10.1007/s00404-017-4526-2
pubmed: 28940095
Feng RK, Meng LR, Wang QT, Chen ZJ. Inspiration of the England community pharmacy services for the development of pharmacy in China. China Pharm. 2011;22(44):4215–8.
Red Blood Cell Disorders (Anemia) Group, Hematology Society of Chinese Medical Association. Chinese expert consensus on the application of intravenous iron. Chin J Hematol. 2019;201905:358–62.
Auerbach M, Henry D, Derman RJ, Achebe MM, Thomsen LL, Glaspy J. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019;94(9):1007–14. https://doi.org/10.1002/ajh.25564 .
doi: 10.1002/ajh.25564
pubmed: 31243803
pmcid: 6772897
Pollock RF, Muduma G. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment. Expert Rev Hematol. 2019;12(2):129–36. 10.1080/ 17474086.2019.1575202.
doi: 10.1080/17474086.2019.1575202
pubmed: 30689458
Yu W, Liu C, Bi Z. Effect of recombinant human erythropoietin combined with iron sucrose on postoperative hemoglobin in patients undergoing artificial joint replacement. Sci Rep. 2023;13(1):18919. https://doi.org/10.1038/s41598-023-41887-8 .
doi: 10.1038/s41598-023-41887-8
pubmed: 37919317
pmcid: 10622435
Das SN, Devi A, Mohanta BB, Choudhury A, Swain A, Thatoi PK. Oral versus intravenous iron therapy in iron deficiency anemia: an observational study. J Family Med Prim Care. 2020;9(7):3619–22. https://doi.org/10.4103/jfmpc.jfmpc_559_20 .
doi: 10.4103/jfmpc.jfmpc_559_20
pubmed: 33102339
pmcid: 7567229
Guanche-Sicilia A, Sánchez-Gómez MB, Castro-Peraza ME, Rodríguez-Gómez JÁ, Gómez-Salgado J, Duarte-Clíments G. Prevention and treatment of phlebitis secondary to the insertion of a peripheral venous catheter: a scoping review from a nursing perspective. Healthc (Basel). 2021;9(5):611. https://doi.org/10.3390/healthcare9050611 .
doi: 10.3390/healthcare9050611
Ramos JG, Leavitt AD, Rosenstein MG. Phlebitis after intravenous Iron sucrose administration in postpartum women. Obstet Gynecol. 2020;136(1):167–9. https://doi.org/10.1097/AOG.0000000000003934 .
doi: 10.1097/AOG.0000000000003934
pubmed: 32541278
Julia R, Melissa R, Andrew L. Phlebitis after parenteral iron sucrose administration in postpartum women. Blood. 2018;132(1):1052. https://doi.org/10.1182/blood-2018-99-113182 .
doi: 10.1182/blood-2018-99-113182